Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer
Launched by SARA MAHMOUD AHMED MAHMOUD · Dec 6, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the benefits of giving chemotherapy before surgery for patients with muscle-invasive bladder cancer (MIBC). MIBC is a serious type of bladder cancer that can spread quickly and is often treated with a major surgery called radical cystectomy, which involves removing the bladder. However, many patients still have a risk of cancer returning after surgery. The trial aims to find out if receiving chemotherapy first can improve survival rates and overall outcomes for these patients.
To participate in this trial, individuals must be over 18 years old and have a confirmed diagnosis of MIBC that has been treated with a specific type of chemotherapy before surgery. Unfortunately, those with non-muscle invasive bladder cancer, patients whose cancer has already spread to other parts of the body, or individuals who have had surgery before chemotherapy will not be eligible. The trial is not yet recruiting participants, but it represents an important step in exploring better treatment options for bladder cancer patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18
- • histological proven MIBC patient treated with neoadjuvant systemic chemotherapy( platinum based )
- Exclusion Criteria:
- • Non muscle invasive bladder cancer (NMIBC)
- • Metastatic patients
- • Patients treated with surgery firstly
About Sara Mahmoud Ahmed Mahmoud
Sara Mahmoud Ahmed Mahmoud is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, she leads and oversees clinical trials that adhere to the highest ethical standards and regulatory requirements. Her extensive experience in clinical research management enables her to effectively coordinate multidisciplinary teams, ensuring the trials are conducted efficiently and with integrity. Sara is passionate about fostering collaboration between researchers, healthcare professionals, and participants, ultimately driving the development of groundbreaking treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Rehab Farouk Mohamed, Professor
Study Director
Assiut University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported